Managed Healthcare Executive December 26, 2024
Laura Joszt, MA

Cardiomyopathies currently have no cures, but many of these disorders are prime candidates for gene therapies.

Treatments for cardiomyopathy may address the symptoms of the disease or slow the progression of it but are not curative. In addition to pharmacological treatment options, patients can undergo surgery or make lifestyle changes to address their cardiomyopathy.

However, gene therapy may present a life-changing option for a cure. In a new review published in the International Journal of Molecular Sciences, authors from Italy reviewed the ongoing clinical trials and future goals.

“Traditional treatment modalities, including medications, lifestyle modifications, and, in some cases, surgical interventions, have offered varying degrees of success but fall short in addressing the underlying genetic causes of these disorders,” the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
STAT+: 3 trends to watch in biotech in 2025
The GLP-1 dilemma persists into 2025
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs

Share This Article